Seroprevalence of dengue, Zika, yellow fever and West Nile viruses in Senegal, West Africa

Competing Interest Statement

BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company focused on T cell-based diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.

Funding Statement

We would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson Medical School, and The Child Health Institute of New Jersey for their continued support. The funders had no role in writing of the manuscript or decision to publish the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The samples included in our study were originally collected as part of malaria and non-malarial surveillance among residents of Sindia, Thies, and Kedougou, Senegal. Samples from Sindia and Thies were part of the surveillance of non-malarial febrile illnesses, while samples from Kedougou were part of genomic surveillance of malaria. Informed consent was obtained from all subjects and/or their legal guardians for the initial sample collection as well as for its future use. All methods were performed in accordance with the guidelines and regulations set forth by the Declaration of Helsinki. The primary studies under which the samples and data were collected received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding data were banked and de-identified prior to the analyses. This study received and exemption determination from the Rutgers Robert Wood Johnson Medical School IRB.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes